KR102579524B1 - 폐, 비강, 설하 및/또는 인두 전달을 위해 조정된 하나 이상의 생활성 화합물로 로딩된 다공성 실리카 입자의 제조 방법 - Google Patents
폐, 비강, 설하 및/또는 인두 전달을 위해 조정된 하나 이상의 생활성 화합물로 로딩된 다공성 실리카 입자의 제조 방법 Download PDFInfo
- Publication number
- KR102579524B1 KR102579524B1 KR1020197035080A KR20197035080A KR102579524B1 KR 102579524 B1 KR102579524 B1 KR 102579524B1 KR 1020197035080 A KR1020197035080 A KR 1020197035080A KR 20197035080 A KR20197035080 A KR 20197035080A KR 102579524 B1 KR102579524 B1 KR 102579524B1
- Authority
- KR
- South Korea
- Prior art keywords
- particles
- silica particles
- bioactive
- bioactive compounds
- loaded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
- C01B33/124—Preparation of adsorbing porous silica not in gel form and not finely divided, i.e. silicon skeletons, by acidic treatment of siliceous materials
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/14—Pore volume
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/16—Pore diameter
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1750544-7 | 2017-05-04 | ||
| SE1750544 | 2017-05-04 | ||
| PCT/EP2018/061436 WO2018202818A1 (en) | 2017-05-04 | 2018-05-03 | A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190142386A KR20190142386A (ko) | 2019-12-26 |
| KR102579524B1 true KR102579524B1 (ko) | 2023-09-18 |
Family
ID=62143135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197035080A Active KR102579524B1 (ko) | 2017-05-04 | 2018-05-03 | 폐, 비강, 설하 및/또는 인두 전달을 위해 조정된 하나 이상의 생활성 화합물로 로딩된 다공성 실리카 입자의 제조 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11285107B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3618811B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7048642B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102579524B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110603034A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018262708B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059099C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3618811T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2837675T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3618811T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018202818A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3618811T3 (da) | 2017-05-04 | 2020-12-21 | Nanologica Ab | Fremgangsmåde til fremstilling af porøse siliciumdioxidpartikler ladet med mindst én biologisk aktiv forbindelse, der er tilpasset til pulmonal, nasal, sublingual og/eller pharyngeal tilførsel |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
| IL286273B2 (en) * | 2019-03-24 | 2025-11-01 | Buzzelet Development And Technologies Ltd | Cannabis inhalation products and methods of production thereof |
| JP7394493B2 (ja) * | 2019-07-31 | 2023-12-13 | レモネックス インコーポレイテッド | 抗癌剤および多孔性シリカ粒子の製造方法 |
| GB201916121D0 (en) | 2019-11-06 | 2019-12-18 | Vicore Pharma Ab | New compositions |
| GB201916117D0 (en) | 2019-11-06 | 2019-12-18 | Vicore Pharma Ab | New compositions |
| GB201916130D0 (en) | 2019-11-06 | 2019-12-18 | Vicore Pharma Ab | New compositions |
| GB201916122D0 (en) | 2019-11-06 | 2019-12-18 | Nanologica Ab | New compositions |
| WO2021211738A1 (en) * | 2020-04-15 | 2021-10-21 | Sanford Burnham Prebys Medical Discovery Institute | Methods and compositions for antiviral treatment |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| GB2355711B (en) | 1999-10-27 | 2003-12-24 | Agilent Technologies Inc | Porous silica microsphere scavengers |
| US6485707B2 (en) | 2001-02-15 | 2002-11-26 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6544497B2 (en) | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6596262B2 (en) | 2001-02-15 | 2003-07-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| GB0118689D0 (en) | 2001-08-01 | 2001-09-19 | Psimedica Ltd | Pharmaceutical formulation |
| US20040242729A1 (en) | 2003-05-30 | 2004-12-02 | 3M Innovative Properties Company | Stabilized particle dispersions containing surface-modified inorganic nanoparticles |
| FI20060428L (fi) | 2006-05-03 | 2007-11-04 | Esko Kauppinen | Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia |
| US20100116743A1 (en) | 2007-06-04 | 2010-05-13 | James Neil Pryor | Silica particles and methods of making and using the same |
| GB0714134D0 (en) | 2007-07-19 | 2007-08-29 | Norton Healthcare Ltd | Dry-powder medicament |
| CA2698683A1 (en) | 2007-09-07 | 2009-03-12 | Epigenesis Pharmaceuticals, Llc | Dheas inhalation compositions |
| WO2009101110A2 (en) | 2008-02-11 | 2009-08-20 | Alfonso Garcia-Bennet | Method for manufacturing mesoporous materials, materials so produced and use of mesoporous materials. |
| JP5437232B2 (ja) | 2008-03-11 | 2014-03-12 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
| JP6073788B2 (ja) | 2010-09-14 | 2017-02-01 | ナノロジカ アクティエボラーグ | 難水溶性医薬及び化粧品有効成分のための過飽和送達媒体 |
| GB201212866D0 (en) * | 2012-07-20 | 2012-09-05 | Formac Pharmaceuticals Nv | Dry granulates of mesoporous silica powders |
| PL3104853T3 (pl) | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych |
| WO2016013751A1 (ko) * | 2014-07-22 | 2016-01-28 | 주식회사 레모넥스 | 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도 |
| US20160090603A1 (en) * | 2014-09-30 | 2016-03-31 | Sandia Corporation | Delivery platforms for the domestication of algae and plants |
| WO2017023407A2 (en) * | 2015-06-01 | 2017-02-09 | Stc. Unm | Nanobiocomposite compositions and methods |
| ES2965015T3 (es) * | 2016-02-29 | 2024-04-10 | Emplicure Ab | Dispositivos de evaporación e inhalación de principios activos |
| DK3618811T3 (da) | 2017-05-04 | 2020-12-21 | Nanologica Ab | Fremgangsmåde til fremstilling af porøse siliciumdioxidpartikler ladet med mindst én biologisk aktiv forbindelse, der er tilpasset til pulmonal, nasal, sublingual og/eller pharyngeal tilførsel |
-
2018
- 2018-05-03 DK DK18723453.9T patent/DK3618811T3/da active
- 2018-05-03 CA CA3059099A patent/CA3059099C/en active Active
- 2018-05-03 EP EP18723453.9A patent/EP3618811B1/en active Active
- 2018-05-03 JP JP2019560246A patent/JP7048642B2/ja not_active Expired - Fee Related
- 2018-05-03 KR KR1020197035080A patent/KR102579524B1/ko active Active
- 2018-05-03 CN CN201880029084.8A patent/CN110603034A/zh active Pending
- 2018-05-03 US US16/609,854 patent/US11285107B2/en not_active Expired - Fee Related
- 2018-05-03 AU AU2018262708A patent/AU2018262708B2/en not_active Ceased
- 2018-05-03 PL PL18723453T patent/PL3618811T3/pl unknown
- 2018-05-03 ES ES18723453T patent/ES2837675T3/es active Active
- 2018-05-03 WO PCT/EP2018/061436 patent/WO2018202818A1/en not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| Xueting Li, et al., Aerosol droplet delivery of mesoporous silica nanoparticles: A strategy for respiratory-based theraeputics, Nanomedicine, 2015, 11, 1377-1385. (2015.03.25.)* |
| 공개특허공보 제10-2016-0011565호 (2016.02.01.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3059099A1 (en) | 2018-11-08 |
| US11285107B2 (en) | 2022-03-29 |
| DK3618811T3 (da) | 2020-12-21 |
| JP7048642B2 (ja) | 2022-04-05 |
| EP3618811A1 (en) | 2020-03-11 |
| CA3059099C (en) | 2023-06-27 |
| AU2018262708A1 (en) | 2019-11-28 |
| WO2018202818A1 (en) | 2018-11-08 |
| ES2837675T3 (es) | 2021-07-01 |
| US20200069588A1 (en) | 2020-03-05 |
| CN110603034A (zh) | 2019-12-20 |
| EP3618811B1 (en) | 2020-09-30 |
| KR20190142386A (ko) | 2019-12-26 |
| AU2018262708B2 (en) | 2021-06-03 |
| PL3618811T3 (pl) | 2021-04-06 |
| JP2020518620A (ja) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3059099C (en) | A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery | |
| AU2009272444B2 (en) | Process for improving crystallinity of fluticasone particles | |
| JP4792457B2 (ja) | 高度に呼吸に適したインスリンのマイクロ粒子 | |
| ES2675575T3 (es) | Proceso para preparar partículas vehículo para polvos secos para inhalación | |
| CN110996912A (zh) | 用于鼻内递送的干粉组合物 | |
| JP2005507881A (ja) | 乾燥粉末医薬製剤 | |
| AU2007208998A1 (en) | A method of producing porous microparticles | |
| JP2020518620A5 (cg-RX-API-DMAC7.html) | ||
| CN114206322B (zh) | 载体基制剂及相关方法 | |
| Carvalho et al. | Dry powder inhalation for pulmonary delivery: recent advances and continuing challenges | |
| CN112469395A (zh) | 间质性肺病的新治疗 | |
| Paul et al. | Potentials and challenges of Levodopa particle formulation for treatment of Parkinson’s disease through intranasal and pulmonary delivery | |
| JP2004517834A (ja) | 粒子吸入キャリア | |
| JP2021510723A (ja) | 吸入型治療薬の高用量送達 | |
| Hamedani et al. | A novel particle engineering method for the production of inhalable cromolyn sodium powders by a combination of spray drier and nebulizer | |
| Peštálová et al. | Modern trends in the formulation of microparticles for lung delivery using porogens: methods, principles and examples | |
| WO2021090013A1 (en) | New composition comprising amorphous nanoporous silica particles | |
| HK40014165A (en) | A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery | |
| El-Gendy et al. | Particle engineering technologies for pulmonary drug delivery | |
| CN116763797B (zh) | 一种药物组合微球、其制备方法及其原料组合物 | |
| Ong | The aerosol performance and physico-chemical properties of co-milled dry powder formulations for high dose delivery | |
| WO2008134817A1 (en) | Composite carriers for dry powder inhalation therapy | |
| Meenach et al. | Characterization and Aerosol Dispersion Performance of Spray-Dried Chemotherapeutic PEGylated Phospholipid Particles for Dry Powder Inhalation Delivery in Lung Cancer | |
| IT202000021292A1 (it) | Composizione in forma di polvere a base di microparticelle incorporanti nanoparticelle per la veicolazione di composti terapeutici/diagnostici | |
| Zhang | Synthesis of rough-surface carriers for dry powder inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20191127 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210127 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230403 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230727 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230913 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230913 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |